These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36060696)

  • 1. gH625-liposomes deliver PACAP through a dynamic
    Barra T; Falanga A; Bellavita R; Laforgia V; Prisco M; Galdiero S; Valiante S
    Front Physiol; 2022; 13():932099. PubMed ID: 36060696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. gH625-liposomes as tool for pituitary adenylate cyclase-activating polypeptide brain delivery.
    Iachetta G; Falanga A; Molino Y; Masse M; Jabès F; Mechioukhi Y; Laforgia V; Khrestchatisky M; Galdiero S; Valiante S
    Sci Rep; 2019 Jun; 9(1):9183. PubMed ID: 31235716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson's Disease.
    Barra T; Falanga A; Bellavita R; Pisano J; Laforgia V; Prisco M; Galdiero S; Valiante S
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lipopolysaccharide on the transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier.
    Nonaka N; Shioda S; Banks WA
    Exp Neurol; 2005 Jan; 191(1):137-44. PubMed ID: 15589520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine.
    Amin FM; Schytz HW
    J Headache Pain; 2018 May; 19(1):35. PubMed ID: 29785578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat.
    Somogyvári-Vigh A; Pan W; Reglödi D; Kastin AJ; Arimura A
    Regul Pept; 2000 Jul; 91(1-3):89-95. PubMed ID: 10967205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects.
    Dogrukol-Ak D; Tore F; Tuncel N
    Curr Pharm Des; 2004; 10(12):1325-40. PubMed ID: 15134484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TAT peptide endows PACAP with an enhanced ability to traverse bio-barriers.
    Yu R; Zeng Z; Guo X; Zhang H; Liu X; Ding Y; Chen J
    Neurosci Lett; 2012 Oct; 527(1):1-5. PubMed ID: 22939769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating polypeptide: Protective effects in stroke and dementia.
    Nonaka N; Banks WA; Shioda S
    Peptides; 2020 Aug; 130():170332. PubMed ID: 32445876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
    Somogyvári-Vigh A; Reglodi D
    Curr Pharm Des; 2004; 10(23):2861-89. PubMed ID: 15379674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model.
    Lamine A; Létourneau M; Doan ND; Maucotel J; Couvineau A; Vaudry H; Chatenet D; Vaudry D; Fournier A
    Neuropharmacology; 2016 Sep; 108():440-50. PubMed ID: 26006268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyclic AMP effects and neuroprotective activities of PACAP and VIP in cultured astrocytes and neurons exposed to oxygen-glucose deprivation.
    Jóźwiak-Bębenista M; Kowalczyk E; Nowak JZ
    Pharmacol Rep; 2015 Apr; 67(2):332-8. PubMed ID: 25712659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maltodextrin modified liposomes for drug delivery through the blood-brain barrier.
    Gurturk Z; Tezcaner A; Dalgic AD; Korkmaz S; Keskin D
    Medchemcomm; 2017 Jun; 8(6):1337-1345. PubMed ID: 30108846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in rats.
    Valiante S; Falanga A; Cigliano L; Iachetta G; Busiello RA; La Marca V; Galdiero M; Lombardi A; Galdiero S
    Int J Nanomedicine; 2015; 10():1885-98. PubMed ID: 25792823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shuttle-mediated nanoparticle delivery to the blood-brain barrier.
    Guarnieri D; Falanga A; Muscetti O; Tarallo R; Fusco S; Galdiero M; Galdiero S; Netti PA
    Small; 2013 Mar; 9(6):853-62. PubMed ID: 23135878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo.
    Reglodi D; Kiss P; Lubics A; Tamas A
    Curr Pharm Des; 2011; 17(10):962-72. PubMed ID: 21524257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of PACAP for neurodegenerative diseases.
    Yang R; Jiang X; Ji R; Meng L; Liu F; Chen X; Xin Y
    Cell Mol Biol Lett; 2015 Jun; 20(2):265-78. PubMed ID: 26204407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons.
    Banks WA; Uchida D; Arimura A; Somogyvári-Vigh A; Shioda S
    Ann N Y Acad Sci; 1996 Dec; 805():270-7; discussion 277-9. PubMed ID: 8993409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of flow on targeting and penetration of angiopep-decorated nanoparticles in a microfluidic model blood-brain barrier.
    Papademetriou I; Vedula E; Charest J; Porter T
    PLoS One; 2018; 13(10):e0205158. PubMed ID: 30300391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.
    Brown D; Tamas A; Reglödi D; Tizabi Y
    J Mol Neurosci; 2013 Jul; 50(3):600-7. PubMed ID: 23625270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.